Rafferty Asset Management LLC Grows Stock Holdings in Vera Therapeutics, Inc. $VERA

Rafferty Asset Management LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 21.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 87,497 shares of the company’s stock after buying an additional 15,429 shares during the quarter. Rafferty Asset Management LLC’s holdings in Vera Therapeutics were worth $2,543,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in Vera Therapeutics by 6.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,190,653 shares of the company’s stock valued at $92,720,000 after acquiring an additional 189,545 shares in the last quarter. Vestal Point Capital LP boosted its stake in shares of Vera Therapeutics by 24.0% in the second quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after purchasing an additional 600,000 shares during the period. Geode Capital Management LLC grew its holdings in shares of Vera Therapeutics by 7.7% in the second quarter. Geode Capital Management LLC now owns 1,294,958 shares of the company’s stock valued at $30,513,000 after purchasing an additional 92,149 shares in the last quarter. American Century Companies Inc. increased its stake in Vera Therapeutics by 89.3% during the 2nd quarter. American Century Companies Inc. now owns 714,428 shares of the company’s stock worth $16,832,000 after buying an additional 336,978 shares during the period. Finally, MPM Bioimpact LLC lifted its holdings in Vera Therapeutics by 35.4% during the 2nd quarter. MPM Bioimpact LLC now owns 563,075 shares of the company’s stock worth $13,266,000 after buying an additional 147,356 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Trading Up 0.9%

NASDAQ:VERA opened at $39.65 on Thursday. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $56.05. The stock has a market cap of $2.78 billion, a P/E ratio of -8.51 and a beta of 1.17. The company has a debt-to-equity ratio of 0.12, a quick ratio of 13.64 and a current ratio of 13.64. The stock has a 50-day simple moving average of $45.45 and a 200-day simple moving average of $35.98.

Vera Therapeutics (NASDAQ:VERA) last posted its earnings results on Wednesday, February 25th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period in the previous year, the firm posted ($0.72) earnings per share. As a group, analysts anticipate that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, CFO Sean Grant sold 4,949 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $207,759.02. Following the transaction, the chief financial officer owned 114,181 shares of the company’s stock, valued at approximately $4,793,318.38. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marshall Fordyce sold 16,925 shares of Vera Therapeutics stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $710,511.50. Following the sale, the chief executive officer owned 257,163 shares in the company, valued at $10,795,702.74. This trade represents a 6.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 33,490 shares of company stock worth $1,405,910. 16.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

VERA has been the subject of several research reports. Evercore boosted their price target on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. HC Wainwright boosted their target price on Vera Therapeutics from $90.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday. Bank of America increased their price target on Vera Therapeutics from $48.00 to $66.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Wedbush boosted their price objective on Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Finally, JPMorgan Chase & Co. cut their target price on shares of Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a research note on Friday, December 19th. Nine equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $80.80.

Vera Therapeutics Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.